Chronic administration of dimebon ameliorates pathology in Tau P301S transgenic mice

Journal of Alzheimer's Disease

Volumn 33, Issue 4, 2013, Pages 1041-1049

  Peters, Owen M ^a   Connor Robson, Natalie ^a   Sokolov, Vladimir B ^b   Aksinenko, Alexey Yu ^b   Kukharsky, Michail S ^b,c   Bachurin, Sergey O ^b   Ninkina, Natalia ^a,b,c   Buchman, Vladimir L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

Alzheimer's disease; dimebolin; latrepirdine; tauopathy; therapeutics; transgenic mice

Indexed keywords

DIMEBON; GAMMA CARBOLINE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; DRUG DOSE INCREASE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAUOPATHY; TRANSGENIC MOUSE;

EID: 84873642177     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121732     Document Type: Article

References (36)

1. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V, Grigorieva I, Ivanov Y, Sablin S, Zefirov N (2001) Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 939, 425-435
2. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of Dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-To-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 372, 207-215
3. Jones RW (2010) Dimebon disappointment. Alzheimers Res Ther 2, 25
4. Grigorev VV, Dranyi OA, Bachurin SO (2003) Comparative study of action mechanisms of Dimebon and memantine on AMPA-And NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 136, 474-477
5. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA, Qian J, Marino MJ (2009) Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 78, 1035-1042
6. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T, Altar CA, Wronski R, Hutter-Paier B, Protter AA (2010) Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-Aspartate receptor antagonism. J Pharmacol Exp Ther 333, 748-757
7. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993, 334-344; discussion 345-339
8. Naga KK, Geddes JW (2011) Dimebon inhibits calciuminduced swelling of rat brain mitochondria but does not alter calcium retention or cytochrome C release. Neuromolecular Med 13, 31-36
9. Zhang S, Hedskog L, Petersen CA,Winblad B, AnkarcronaM (2010) Dimebon (latrepirdine) enhances mitochondrial function and protects neuronal cells from death. J Alzheimers Dis 21, 389-402
10. Bachurin SO, Shelkovnikova TA, Ustyugov AA, Peters O, Khritankova I, Afanasieva MA, Tarasova TV, Alentov II, Buchman VL, Ninkina NN (2011) Dimebon slows progression of proteinopathy in gamma-synuclein transgenic mice. Neurotox Res 22, 33-42
11. Shelkovnikova TA, Ustyugov AA, Millership S, Peters O, Anichtchik O, Spillantini MG, Buchman VL, Bachurin SO, Ninkina NN (2011) Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. Neurodegener Dis 8, 430-437
12. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M, Zhao W, Ho L, Pasinetti GM (2011) Preclinical study of Dimebon on beta-Amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 6, 7
13. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL,Westaway D, Fraser P, Hyslop PS, Sano M, Bezprozvanny I, Ehrlich ME, Holtzman DM, Gandy S (2009) Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 4, 51
14. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, Ninkina N, Bachurin SO, Akiyama H, Goedert M, Hasegawa M (2009) Methylene blue and Dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 583, 2419-2424
15. Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G, Wang R, Ringe D, Fraser P, Westaway D, St George-Hyslop PH, Szabo P, Relkin NR, Buxbaum JD, Glabe CG, Protter AA, Martins RN, Ehrlich ME, Petsko GA, Yue Z, Gandy S (2012) Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry, doi: 10.1038/mp.2012.1066
16. Steele JW, Ju S, Lachenmayer ML, Liken J, Stock A, Kim SH, Delgado LM, Alfaro IE, Bernales S, Verdile G, Bharadwaj P, Gupta V, Barr R, Friss A, Dolios G,Wang R, Ringe D, Protter AA, Martins RN, Ehrlich ME, Yue Z, Petsko GA, Gandy S (2012) Latrepirdine stimulates autophagy and reduces accumulation of alpha-synuclein in cells and in mouse brain. Mol Psychiatry, doi: 10.1038/mp.2012.1155
17. Bharadwaj PR, Verdile G, Barr RK, Gupta V, Steele JW, Lachenmayer ML, Yue Z, Ehrlich ME, Petsko G, Ju S, Ringe D, Sankovich SE, Caine JM, Macreadie IG, Gandy S, Martins RN (2012) Latrepirdine (Dimebon) enhances autophagy and reduces intracellular GFP-A42 levels in yeast. J Alzheimers Dis, doi: 10.3233/JAD-2012-1201788
18. Eckert SH, Eckmann J, Renner K, Eckert GP, Leuner K, Mueller WE (2012) Dimebon ameliorates amyloid-induced impairments of mitochondrial form and function. J Alzheimers Dis 31, 21-32
19. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yoshida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A, Crowther RA, Ghetti B, Spillantini MG, Goedert M (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22, 9340-9351
20. Scattoni ML, Gasparini L, Alleva E, Goedert M, Calamandrei G, Spillantini MG (2010) Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res 208, 250-257
21. Peters OM, Millership S, Shelkovnikova TA, Soto I, Keeling L, Hann A, Marsh-Armstrong N, Buchman VL, Ninkina N (2012) Selective pattern of motor system damage in gammasynuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis. Neurobiol Dis 48, 124-131
22. Ninkina N, Peters O, Millership S, Salem H, van der Putten H, Buchman VL (2009) Gamma-synucleinopathy: Neurodegeneration associated with overexpression of the mouse protein. Hum Mol Genet 18, 1779-1794
23. Buchman VL, Hunter HJ, Pinon LG, Thompson J, Privalova EM, Ninkina NN, Davies AM (1998) Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J Neurosci 18, 9335-9341
24. Robertson DC, Schmidt O, Ninkina N, Jones PA, Sharkey J, Buchman VL (2004) Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice. J Neurochem 89, 1126-1136
25. Goedert M, Jakes R, Vanmechelen E (1995) Monoclonal antibodyAT8 recognises tau protein phosphorylated at both serine 202 and threonine 205. Neurosci Lett 189, 167-169
26. Mizushima N, Yoshimori T (2007) How to interpret LC3 immunoblotting. Autophagy 3, 542-545
27. Yata K, Oikawa S, Sasaki R, Shindo A, Yang R, Murata M, Kanamaru K, TomimotoH(2011) Astrocytic neuroprotection through induction of cytoprotective molecules; A proteomic analysis of mutant P301S tau-Transgenic mouse. Brain Res 1410, 12-23
28. Bellucci A,Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG (2004) Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 165, 1643-1652
29. Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70, 410-426
30. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G, Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Lee VM, Trojanowski JQ (2005) Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci U S A 102, 227-231
31. Zhang B, Carroll J, Trojanowski JQ, Yao Y, Iba M, Potuzak JS, Hogan AM, Xie SX, Ballatore C, Smith AB 3rd, Lee VM, Brunden KR (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 32, 3601-3611
32. Wang Y, Mandelkow E (2012) Degradation of tau protein by autophagy and proteasomal pathways. Biochem Soc Trans 40, 644-652
33. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A, Gouras GK, Greengard P, Xu H (2003) Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci U S A 100, 721-726
34. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, Pangalos MN, Schmitt I, Wullner U, Evert BO, O'Kane CJ, Rubinsztein DC (2006) Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet 15, 433-442
35. Majumder S, Richardson A, Strong R, Oddo S (2011) Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 6, e25416
36. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, GoedertM(2012) Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain 135, 2169-2177